Literature DB >> 24310563

Laparoscopic adjustable gastric banding and progression from impaired fasting glucose to diabetes.

John M Wentworth1, Tamishta Hensman, Julie Playfair, Cheryl Laurie, Matthew E Ritchie, Wendy A Brown, Stewart Skinner, Jonathan E Shaw, Paul E O'Brien.   

Abstract

AIMS/HYPOTHESIS: Obesity and dysglycaemia are major risk factors for type 2 diabetes. We determined if obese people undergoing laparoscopic adjustable gastric banding (LAGB) had a reduced risk of progressing from impaired fasting glucose (IFG) to diabetes.
METHODS: This was a retrospective cohort study of obese people with IFG who underwent LAGB. Weight and diabetes outcomes after a minimum follow-up period of 4 years (mean ± SD 6.1 ± 1.7 years) were compared with those of Australian adults with IFG from a population-based study (AusDiab).
RESULTS: We identified 281 LAGB patients with baseline IFG. Their mean ± SD age and BMI were 46 ± 9 years and 46 ± 9 kg/m(2), respectively. The diabetes incidence for patients in the lowest, middle and highest weight loss tertile were 19.1, 3.4 and 1.8 cases/1,000 person-years, respectively. The AusDiab cohort had a lower BMI (28 ± 5 kg/m(2)) and a diabetes incidence of 12.5 cases/1,000 person-years. This increased to 20.5 cases/1,000 person-years when analysis was restricted to the 322 obese AusDiab participants, which was higher than the overall rate of 8.2 cases/1,000 person-years seen in the LAGB group (p = 0.02). Multivariable analysis of the combined LAGB and AusDiab data suggested that LAGB was associated with ∼75% lower risk of diabetes (OR 0.24 [95% CI 0.10, 0.57], p = 0.004). CONCLUSIONS/
INTERPRETATION: In obese people with IFG, weight loss after LAGB is associated with a substantially reduced risk of progressing to diabetes over ≥4 years. Bariatric surgery may be an effective diabetes prevention strategy in this population.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24310563     DOI: 10.1007/s00125-013-3129-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  26 in total

1.  The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).

Authors:  A Ramachandran; C Snehalatha; S Mary; B Mukesh; A D Bhaskar; V Vijay
Journal:  Diabetologia       Date:  2006-01-04       Impact factor: 10.122

2.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

3.  Pioglitazone for diabetes prevention in impaired glucose tolerance.

Authors:  Ralph A DeFronzo; Devjit Tripathy; Dawn C Schwenke; MaryAnn Banerji; George A Bray; Thomas A Buchanan; Stephen C Clement; Robert R Henry; Howard N Hodis; Abbas E Kitabchi; Wendy J Mack; Sunder Mudaliar; Robert E Ratner; Ken Williams; Frankie B Stentz; Nicolas Musi; Peter D Reaven
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

4.  The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study.

Authors:  David W Dunstan; Paul Z Zimmet; Timothy A Welborn; Maximilian P De Courten; Adrian J Cameron; Richard A Sicree; Terry Dwyer; Stephen Colagiuri; Damien Jolley; Matthew Knuiman; Robert Atkins; Jonathan E Shaw
Journal:  Diabetes Care       Date:  2002-05       Impact factor: 19.112

5.  Glucose indices, health behaviors, and incidence of diabetes in Australia: the Australian Diabetes, Obesity and Lifestyle Study.

Authors:  Dianna J Magliano; Elizabeth L M Barr; Paul Z Zimmet; Adrian J Cameron; David W Dunstan; Stephen Colagiuri; Damien Jolley; Neville Owen; Patrick Phillips; Robyn J Tapp; Tim A Welborn; Jonathan E Shaw
Journal:  Diabetes Care       Date:  2007-11-05       Impact factor: 19.112

6.  A population perspective on diabetes prevention: whom should we target for preventing weight gain?

Authors:  James P Burke; Ken Williams; K M Venkat Narayan; Cynthia Leibson; Steven M Haffner; Michael P Stern
Journal:  Diabetes Care       Date:  2003-07       Impact factor: 19.112

7.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

8.  Laparoscopic gastric banding is safe in outpatient surgical centers.

Authors:  Chris Cobourn; David Mumford; Mary Ann Chapman; Leandra Wells
Journal:  Obes Surg       Date:  2010-04       Impact factor: 4.129

9.  Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men.

Authors:  J M Chan; E B Rimm; G A Colditz; M J Stampfer; W C Willett
Journal:  Diabetes Care       Date:  1994-09       Impact factor: 19.112

10.  XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.

Authors:  Jarl S Torgerson; Jonathan Hauptman; Mark N Boldrin; Lars Sjöström
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

View more
  4 in total

Review 1.  The Vasculature in Prediabetes.

Authors:  David H Wasserman; Thomas J Wang; Nancy J Brown
Journal:  Circ Res       Date:  2018-04-13       Impact factor: 17.367

2.  Prediabetes Deserves More Attention: A Review.

Authors:  Yakubu Lawal; Fatima Bello; Yazid Suleiman Kaoje
Journal:  Clin Diabetes       Date:  2020-10

Review 3.  Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action.

Authors:  J Grams; W Timothy Garvey
Journal:  Curr Obes Rep       Date:  2015-06

4.  Conversion from Prediabetes to Diabetes in Individuals with Obesity, 5-Years Post-Band, Sleeve, and Gastric Bypass Surgeries.

Authors:  Dror Dicker; Doron S Comaneshter; Rina Yahalom; Chagit Adler Cohen; Shlomo Vinker; Rachel Golan
Journal:  Obes Surg       Date:  2019-12       Impact factor: 4.129

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.